Table 1.
Demographic data and medical history (n = 76) as well as frequency of adverse events (large local and systemic reactions) during up‐dosing and maintenance phases
| Age range (median age) (y) | 19‐70 (50) |
|---|---|
| Sex | |
| Male | 43 (56.6%) |
| Female | 33 (43.4%) |
| Antihypertensive treatment | 10 (13.2%) |
| ACE inhibitor | 3 (3.9%) |
| Beta blocker | 5 (6.6%) |
| ACE inhibitor and beta blocker | 2 (2.6%) |
| Grade of SR (index sting)a | |
| I° | 3 (3.9%) |
| II° | 56 (73.7%) |
| III° | 16 (21.1%) |
| IV° | 1 (1.3%) |
| Up‐dosing phase (n = 76) | |
| No side effect | 45 (59.2%) |
| Large local reaction | 22 (28.9%) |
| Subjective systemic symptoms | 5 (6.6%) |
| Objective systemic symptoms | 3 (3.9%) |
| Maintenance phase (n = 67) | |
| No side effect | 56 (83.6%) |
| Large local reaction | 10 (14.9%) |
| Subjective systemic symptoms | 1 (1.5%) |
| Objective systemic symptoms | 0 (0.0%) |
a
According to the classification of Ring & Messmer.4